Berberine Administration in Treatment of Colitis: A Review.


Journal

Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531

Informations de publication

Date de publication:
2020
Historique:
received: 06 02 2020
revised: 31 03 2020
accepted: 23 04 2020
pubmed: 23 6 2020
medline: 22 9 2021
entrez: 23 6 2020
Statut: ppublish

Résumé

Berberine (Brb) is one of the well-known naturally occurring compounds exclusively found in Berberis vulgaris and other members of this family, such as Berberis aristata, Berberis aroatica, and Berberis aquifolium. This plant-derived natural compound has a variety of therapeutic impacts, including anti-oxidant, anti-inflammatory, anti-diabetic, and anti-tumor. Multiple studies have demonstrated that Brb has great anti-inflammatory activity and is capable of reducing the levels of proinflammatory cytokines, while it enhances the concentrations of anti-inflammatory cytokines, making it suitable for the treatment of inflammatory disorders. Colitis is an inflammatory bowel disease with chronic nature. Several factors are involved in the development of colitis and it appears that inflammation and oxidative stress are the most important ones. With respect to the anti-inflammatory and antioxidant effects of Brb, its administration seems to be beneficial in the treatment of colitis. In the present review, the protective effects of Brb in colitis treatment and its impact on molecular pathways are discussed.

Identifiants

pubmed: 32564751
pii: CDT-EPUB-107531
doi: 10.2174/1389450121666200621193758
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Antioxidants 0
Cytokines 0
Plant Extracts 0
Berberine 0I8Y3P32UF

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1385-1393

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Milad Ashrafizadeh (M)

Department of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

Masoud Najafi (M)

Radiology and Nuclear Medicine Department, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran

Reza Mohammadinejad (R)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

Tahereh Farkhondeh (T)

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran
Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran

Saeed Samarghandian (S)

Healthy Ageing Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH